If you have been reading about Reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-14. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid, may form a loose cake |
| Solubility class | Soluble in water | Practically insoluble in nonpolar solvents |
| Storage temperature, solid | -20 °C or below | Desiccated and protected from light |
| Storage temperature, liquid | 2-8 °C | Refrigerated, not frozen |
| Typical identity method | LC-MS | Observed mass compared with calculated mass |
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
=== Laver Cup === Zverev took part in the inaugural Laver Cup in Prague in 2017. He accrued four points by winning both of his singles matches for Team Europe as they defeated Team World 15–9. He played a more crucial role in 2018 and 2019, winning the clinching matches in both editions against Kevin Anderson and Milos Raonic respectively. In the 2021 edition in Boston, he defeated John Isner in three sets in his only match in Team Europe's 14–1 win. In 2024, Zverev returned to the Laver Cup after a two-year absence in which Team World had won both editions. He lost his first match to Taylor Fritz, but rebounded on the third day to win against Frances Tiafoe in a deciding match tie-break. In 2025, Zverev failed to win any matches against Team World, losing in straight sets to Alex de Minaur and Taylor Fritz, the latter contributing his sixth consecutive loss against the American and allowing Team World to secure their third Laver Cup title.
The Ural Cossack Host was formed from the Ural Cossacks, who had settled along the Ural River. Their alternative name, Yaik Cossacks, comes from the river's former name, changed by the government after Pugachev's Rebellion of 1773–1775. The Ural Cossacks spoke Russian, and identified as having primarily Russian ancestry, but also incorporated many Tatars into their ranks. In 1577, twenty years after Moscow had conquered the Volga from Kazan to Astrakhan, the government sent troops to disperse pirates and raiders along the Volga. Among them was Yermak Timofeyevich. Some escaped to flee southeast to the Ural River, where they joined the Yaik Cossacks. In 1580, they captured Saraichik. By 1591, they were fighting on behalf of the government in Moscow. Over the next century, they were officially recognized by the imperial government.
Motion of the cephalopods is usually backward as water is forced out anteriorly through the hyponome, but direction can be controlled somewhat by pointing it in different directions. Some cephalopods accompany this expulsion of water with a gunshot-like popping noise, thought to function to frighten away potential predators. Cephalopods employ a similar method of propulsion despite their increasing size (as they grow) changing the dynamics of the water in which they find themselves. Thus their paralarvae do not extensively use their fins (which are less efficient at low Reynolds numbers) and primarily use their jets to propel themselves upwards, whereas large adult cephalopods tend to swim less efficiently and with more reliance on their fins.
Sources: en.wikipedia.org
== Medical uses == In the US, crisaborole is indicated for topical treatment of mild to moderate atopic dermatitis in people three months of age and older. In the EU, crisaborole was authorized for treatment of mild to moderate atopic dermatitis in people two years of age and older with ≤ 40% body surface area (BSA) affected.
=== Packaging === Under section 409 of the Federal Food, Drug, and Cosmetic Act, irradiation of prepackaged foods requires premarket approval for not only the irradiation source for a specific food but also for the food packaging material. Approved packaging materials include various plastic films, yet does not cover a variety of polymers and adhesive based materials that have been found to meet specific standards. The lack of packaging material approval limits manufacturers production and expansion of irradiated prepackaged foods. Approved materials by FDA for Irradiation according to 21 CFR 179.45:
First, adjuvants may help in the translocation of antigens to the lymph nodes where they can be recognized by T cells. This will ultimately lead to greater T cell activity resulting in a heightened clearance of pathogen throughout the organism. Second, adjuvants may provide physical protection to antigens which grants the antigen a prolonged delivery. This means the organism will be exposed to the antigen for a longer duration, making the immune system more robust as it makes use of the additional time by upregulating the production of B and T cells needed for greater immunological memory in the adaptive immune response. Third, adjuvants may help to increase the capacity to cause local reactions at the injection site (during vaccination), inducing greater release of danger signals by chemokine releasing cells such as helper T cells and mast cells. Fourth, they may induce the release of inflammatory cytokines which helps to not only recruit B and T cells at sites of infection but also to increase transcriptional events leading to a net increase of immune cells as a whole. Finally, adjuvants are believed to increase the innate immune response to antigen by interacting with pattern recognition receptors (PRRs) on or within accessory cells.
{\displaystyle {\begin{array}{lll}M({\ce {He}})&=4.002602(2)\times M_{\mathrm {u} }&=4.002602(2){\text{ g/mol}}\\M({\ce {Ne}})&=20.1797(6)\times M_{\mathrm {u} }&=20.1797(6){\text{ g/mol}}\\M({\ce {Fe}})&=55.845(2)\times M_{\mathrm {u} }&=55.845(2){\text{ g/mol}}\\M({\ce {Cu}})&=63.546(3)\times M_{\mathrm {u} }&=63.546(3){\text{ g/mol}}\\M({\ce {Ag}})&=107.8682(2)\times M_{\mathrm {u} }&=107.8682(2){\text{ g/mol}}\end{array}}}
Sources: en.wikipedia.org
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.
Mass spectrometry gives the observed molecular mass, which is compared with the calculated value for the expected sequence. Reversed-phase chromatography shows retention behaviour and main peak purity. Peptide mapping adds sequence-level confirmation when the question requires it.
Typical entries include appearance, chromatographic purity as area percent, observed mass, water or residual solvent content, and the analytical methods used. The document reflects the lot tested and the laboratory that performed the work. It does not by itself establish that the delivered vial matches the tested lot.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.